Collection of Blood for Multiple Collaborative Studies

Collection and Preservation of Blood and Serum Specimens From HIV Positive or HIV Negative Patients for Multiple Collaborative Studies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01336855

Enrollment

2000

Registered

2011-04-18

Start date

1988-01-01

Completion date

2030-01-01

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, Observational, Pathogenesis, Immunology, Virology, Control, Healthy control, Men who have sex with men

Brief summary

This study seeks to confidentially collect blood from HIV-positive individuals and HIV-negative controls to provide basic scientists with specimens for collaborative studies.

Detailed description

HIV positive patients are currently the focus of multiple collaborative research studies, both at UCSF and other institutions. The aims of these research projects include improving the understanding of etiology, immunology, epidemiology and treatment of HIV. There are numerous requests from basic scientists at UCSF for collaborative studies on specimens, especially for blood, saliva and urine samples. Specimens may be used to test such things as virus characteristics, genotyping and/or phenotyping resistance, plasma drug concentrations, immune function or evidence of complications of HIV disease. The samples may also be tested for genetic factors that may be related to the course of HIV disease

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* HIV-1 antibody negative with similar characteristics to HIV-1 positive cohort * HIV-positive subjects naive to antiretroviral therapy * HIV-positive subjects stable on or off antiretroviral therapy for a minimum of 6 months * Good venous access * Able to provide informed consent

Exclusion criteria

* Hemoglobin \< 9g/dl * Hematocrit \< 27% * Active treatment for cancer * Hospitalization or IV antibiotic use within the last 4 months * Immunosuppressive therapy within the last 4 months

Design outcomes

Primary

Measure	Time frame	Description
Plasma HIV RNA level	Ongoing	Viral load

Countries

United States

Contacts

CONTACTRebecca Hoh, M.S., R.D.

Rebecca.Hoh@ucsf.edu415-476-4082

CONTACTViva Tai, MS. RD

Viva.Tai@ucsf.edu415-476-4082

PRINCIPAL_INVESTIGATORSteven Deeks, M.D.

University of Californa, San Francisco

Outcome results